Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

Investor Relations

Latest Financial Results

Q2 2018

Quarter Ended May 31, 2018

Stock Information

Intellipharmaceutics International Inc.
NASDAQ: IPCI
TSX: IPCI:CA

Company Overview

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company’s patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals.  Intellipharmaceutics has developed several drug delivery systems based on this technology platforms, with a pipeline of products (some of which have received FDA approval) in various stages of development.  The Company has ANDA and NDA 505 (b)(2) drug delivery product candidates in its development pipeline in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.

IR Contact Information

Investor Relations

Intellipharmaceutics International Inc.
30 Worcester Road
Toronto, ON M9W 5X2
T: 416-798-3001
investors@intellipharmaceutics.com

Transfer Agent

AST Trust Company (Canada)
1 Toronto Street
Suite 1200
Toronto, ON M5C 2V6
Canada
T: 416-682-3844